Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
Summary
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
Official title: A Multicenter, Randomized, Double-blind, Placebo-Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of THDBH120 Injection in Overweight or Obese Subjects
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
276
Start Date
2025-01-06
Completion Date
2026-03-11
Last Updated
2025-06-25
Healthy Volunteers
No
Conditions
Interventions
THDBH120 injection
Participants received THDBH120 by subcutaneous injection.
Placebo of THDBH120 injection
Participants received placebo by subcutaneous injection.
Locations (1)
The Second Xiangya Hospital of Central South University
Changsha, China